litlas
Log inCreate account

Bruce D. Cheson

Active 1976–2024

Also published as
BRUCE D. CHESON
159
Papers
55,673
Citations
102
h-index
158
i10-index

Citations

Citations per year for Bruce D. Cheson1948: 5 citations1977: 5 citations1978: 8 citations1979: 4 citations1980: 4 citations1981: 4 citations1982: 3 citations1983: 3 citations1984: 4 citations1985: 3 citations1986: 3 citations1987: 4 citations1988: 2 citations1989: 7 citations1990: 19 citations1991: 26 citations1992: 35 citations1993: 35 citations1994: 44 citations1995: 48 citations1996: 47 citations1997: 51 citations1998: 62 citations1999: 77 citations2000: 92 citations2001: 114 citations2002: 179 citations2003: 231 citations2004: 171 citations2005: 198 citations2006: 247 citations2007: 312 citations2008: 313 citations2009: 358 citations2010: 383 citations2011: 363 citations2012: 372 citations2013: 339 citations2014: 397 citations2015: 465 citations2016: 405 citations2017: 440 citations2018: 434 citations2019: 1,390 citations2020: 1,489 citations2021: 1,356 citations2022: 1,047 citations2023: 704 citations2024: 1,080 citations2025: 450 citations2026: 13 citations1949–1976: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,296 citing papers, 27% of this breakdownGermany: 1,410 citing papers, 7.2% of this breakdownItaly: 1,389 citing papers, 7.1% of this breakdownUnited Kingdom: 1,288 citing papers, 6.6% of this breakdownFrance: 1,260 citing papers, 6.4% of this breakdownChina: 907 citing papers, 4.6% of this breakdownSpain: 779 citing papers, 4% of this breakdownCanada: 711 citing papers, 3.6% of this breakdownSwitzerland: 605 citing papers, 3.1% of this breakdownAustralia: 574 citing papers, 2.9% of this breakdownNetherlands: 538 citing papers, 2.7% of this breakdownJapan: 406 citing papers, 2.1% of this breakdown
0%27%Other 22.7%

Institutions

Fields

  • Medicine84.2%
  • Biochemistry, Genetics and Molecular Biology10.4%
  • Immunology and Microbiology2.9%
  • Engineering0.4%
  • Computer Science0.4%
  • Chemistry0.3%
  • Other1.4%

Topics

  • Lymphoma Diagnosis and Treatment15.1%
  • Chronic Lymphocytic Leukemia Research9.1%
  • Acute Myeloid Leukemia Research5.4%
  • CAR-T cell therapy research4.8%
  • CNS Lymphoma Diagnosis and Treatment3.4%
  • Viral-associated cancers and disorders3%
  • Other59.2%

Coauthors

All papers

Open in search
  1. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

    Authors: Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington, Franco Cavalli, Lawrence H. Schwartz, Emanuele Zucca, Tim Lister - Journal of Clinical Oncology 2014 cited by 5,552

  2. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Authors: Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris‐Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, Thomas J. Kipps - Blood 2018 cited by 1,689

  3. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

    Authors: Bruce D. Cheson, John M. Bennett, Kenneth J. Kopecky, Thomas Büchner, Cheryl L. Willman, Elihu H. Estey, Charles A. Schiffer, Hartmut Doehner, Martin S. Tallman, Tim Lister, Francesco Lo‐Coco, Roel Willemze, Andrea Biondi, Wolfgang Hiddemann, Richard A. Larson, Bob Löwenberg, Miguel Á. Sanz, David R. Head, R Ohno, Clara D. Bloomfield - Journal of Clinical Oncology 2003 cited by 2,662

  4. Revised Response Criteria for Malignant Lymphoma

    Authors: Bruce D. Cheson, Beate Pfistner, Malik E. Juweid, Randy D. Gascoyne, Lena Specht, Sandra J. Horning, Bertrand Coiffier, Richard I. Fisher, Anton Hagenbeek, Emanuele Zucca, Steven T. Rosen, Sigrid Stroobants, T. Andrew Lister, Richard T. Hoppe, Martin Dreyling, Kensei Tobinai, Julie M. Vose, Joseph M. Connors, Massimo Federico, Volker Diehl - Journal of Clinical Oncology 2007 cited by 4,448

  5. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

    Authors: Bruce D. Cheson - Blood 2006 cited by 1,588

  6. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group

    Authors: Sally F. Barrington, N. George Mikhaeel, Lale Kostakoğlu, Michel Meignan, Martin Hutchings, Stefan Müeller, Lawrence H. Schwartz, Emanuele Zucca, Richard I. Fisher, Judith Trotman, Otto S. Hoekstra, Rodney J. Hicks, Michael O’Doherty, Roland Hustinx, Alberto Biggi, Bruce D. Cheson - Journal of Clinical Oncology 2014 cited by 1,648

  7. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

    Authors: Nancy L. Bartlett, Wyndham H. Wilson, Sin‐Ho Jung, Eric D. Hsi, Matthew J. Maurer, Levi Pederson, Mei‐Yin C. Polley, Brandelyn N. Pitcher, Bruce D. Cheson, Brad S. Kahl, Jonathan W. Friedberg, Louis M. Staudt, Nina D. Wagner‐Johnston, Kristie A. Blum, Jeremy S. Abramson, Nishitha Reddy, Jane N. Winter, Julie Chang, Ajay K. Gopal, Amy Chadburn, Susan Mathew, Richard I. Fisher, Kristy L. Richards, Heiko Schöder, Andrew D. Zelenetz, John P. Leonard - Journal of Clinical Oncology 2019 cited by 423

  8. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

    Authors: Richard R. Furman, Jeff P. Sharman, Steven Coutré, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger Dansey, Michael Hallek, Susan O’Brien - New England Journal of Medicine 2014 cited by 1,684

  9. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Authors: Anas Younes, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Radhakrishnan Ramchandren, Nancy L. Bartlett, Bruce D. Cheson, Sven de Vos, Andres Forero‐Torres, Craig H. Moskowitz, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dana A. Kennedy, Eric L. Sievers, Robert Chen - Journal of Clinical Oncology 2012 cited by 1,520

  10. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

    Authors: Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian T. Hill, Christina Howlett, Alan P Skarbnik, Bruce D. Cheson, Clive S. Zent, Jeffrey J. Pu, Pavel Kiselev, André Goy, David F. Claxton, Krista M. Isaac, Kaitlin Kennard, Colleen Timlin, Daniel J. Landsburg, Allison Winter, Sunita D. Nasta, Spencer Henick Bachow, Stephen J. Schuster, Colleen Dorsey, Jakub Svoboda, Paul M. Barr, Chaitra S. Ujjani - Haematologica 2018 cited by 452

  11. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

    Authors: Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris‐Cappio, Guillaume Dighiero, Hartmut Döhner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Kanti R. Rai, Thomas J. Kipps - Blood 2008 cited by 3,193

  12. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

    Authors: Bruce D. Cheson, Stephen M. Ansell, Larry Schwartz, Leo I. Gordon, Ranjana H. Advani, Heather A. Jacene, Axel Hoos, Sally F. Barrington, Philippe Armand - Blood 2016 cited by 506

  13. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

    Authors: Jeffrey A. Jones, Anthony R. Mato, William G. Wierda, Matthew S. Davids, Michael Y. Choi, Bruce D. Cheson, Richard R. Furman, Nicole Lamanna, Paul M. Barr, Lang Zhou, Brenda Chyla, Ahmed Hamed Salem, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, Steven Coutré, Jennifer A. Woyach, John C. Byrd - The Lancet Oncology 2017 cited by 378

  14. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

    Authors: Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani, Laurie H. Sehn, Catherine Diefenbach, Kathryn S. Kolibaba, Oliver W. Press, Gilles Salles, Hervé Tilly, Andy I. Chen, Sarit Assouline, Bruce D. Cheson, Martin Dreyling, Anton Hagenbeek, Pier Luigi Zinzani, Surai Jones, Ji Cheng, Dan Lü, Elicia Penuel, Jamie Hirata, Michael Wenger, Yu-Waye Chu, Jeff P. Sharman - The Lancet Haematology 2019 cited by 249

  15. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

    Authors: Bruce D. Cheson, Sandra J. Horning, B Coiffier, Margaret A. Shipp, Richard I. Fisher, Joseph M. Connors, Tim Lister, Julie M. Vose, Antonio J Grillo-López, Anton Hagenbeek, Fernando Cabanillas, Donald Klippensten, Wolfgang Hiddemann, Ronald A. Castellino, Nancy L. Harris, Jamés O. Armitage, William Carter, Richard T. Hoppe, George P. Canellos - Journal of Clinical Oncology 1999 cited by 3,490

  16. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

    Authors: Jeff P. Sharman, Steven Coutré, Richard R. Furman, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Eugen Tausch, Paula Cramer, Julie Huang, Siddhartha Mitra, Michael Hallek, Susan O’Brien, Stephan Stilgenbauer - Journal of Clinical Oncology 2019 cited by 221

  17. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

    Authors: Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Daniel Jones, Raquel Izumi, Melanie M. Frigault, Cheng S. Quah, Rakesh Kumar Raman, Priti Patel, Min Hui Wang, Thomas J. Kipps - Haematologica 2021 cited by 108

  18. Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)

    Authors: James L. Rubenstein, Eric D. Hsi, Jeffrey L. Johnson, Sin‐Ho Jung, Megan O. Nakashima, Barbara Grant, Bruce D. Cheson, Lawrence D. Kaplan - Journal of Clinical Oncology 2013 cited by 499

  19. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

    Authors: Gary J. Kelloff, John M. Hoffman, Bruce E. Johnson, Howard I. Scher, Barry A. Siegel, Edward Y. Cheng, Bruce D. Cheson, Joyce O’Shaughnessy, Kathryn Z. Guyton, David A. Mankoff, Lalitha Shankar, Steven M. Larson, Caroline C. Sigman, Richard L. Schilsky, Daniel C. Sullivan - Clinical Cancer Research 2005 cited by 669

  20. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

    Authors: Matthias Pfeifer, Bing Zheng, Tabea Erdmann, Hartmut Koeppen, Ronald McCord, Michael Grau, Annette M. Staiger, Akiko Chai, Thomas Sandmann, Hannelore Madle, Bernd Dörken, Y-W Chu, A I Chen, Dan I. Lebovic, Gilles Salles, M. S. Czuczman, Maria Corinna Palanca-Wessels, Oliver W. Press, Ranjana H. Advani, Franck Morschhauser, Bruce D. Cheson, Peter Lenz, German Ott, Andrew G. Polson, Kirsten Mundt, Georg Lenz - Leukemia 2015 cited by 152

  21. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial

    Authors: Bruce D. Cheson, Nancy L. Bartlett, Betsy LaPlant, Hun Ju Lee, Ranjana J Advani, Beth Christian, Catherine Diefenbach, Tatyana Feldman, Stephen M. Ansell - The Lancet Haematology 2020 cited by 96

  22. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

    Authors: Nathan Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopińska‐Posłuszny, Chan Y. Cheah, Tycel Phillips, Ewa Lech‐Marańda, Bruce D. Cheson, Paolo F. Caimi, Sebastian Grosicki, Lori A. Leslie, Julio C. Chávez, Gustavo Fonseca, Sunil Babu, Daniel J. Hodson, Spencer H. Shao, John M. Burke, Jeff P. Sharman, Jennie Y. Law, John M. Pagel, Hari P. Miskin, Peter Sportelli, Owen A. O’Connor, Michael Weiss, Pier Luigi Zinzani - Journal of Clinical Oncology 2021 cited by 161

  23. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

    Authors: Laurie H. Sehn, Neil Chua, Jiřı́ Mayer, Gregg Dueck, Marek Trněný, Kamal Bouabdallah, Nathan Fowler, Vincent Delwail, Oliver W. Press, Gilles Salles, John G. Gribben, Anne Lennard, Pieternella J. Lugtenburg, Natalie Dimier, Elisabeth Wassner-Fritsch, Günter Fingerle‐Rowson, Bruce D. Cheson - The Lancet Oncology 2016 cited by 343

  24. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

    Authors: Malik E. Juweid, Sigrid Stroobants, Otto S. Hoekstra, Felix M. Mottaghy, Markus Dietlein, Ali Guermazi, Gregory A. Wiseman, Lale Kostakoğlu, Klemens Scheidhauer, Andreas K. Buck, Ralph Naumann, Karoline Spaepen, Rodney J. Hicks, Wolfgang Weber, Sven N. Reske, Markus Schwaiger, Lawrence H. Schwartz, Josée M. Zijlstra, Barry A. Siegel, Bruce D. Cheson - Journal of Clinical Oncology 2007 cited by 1,336